Tenax Therapeutics Reports Q2 GAAP EPS of -$0.35
Tenax Therapeutics (NASDAQ: TENX) reported a GAAP earnings per share (EPS) loss of $0.35 for the second quarter, which beat analysts' expectations by $0.01. The company also disclosed cash and cash equivalents totaling $118 million as of June 30, 2026. During Q2, Tenax received $13.4 million in proceeds from warrant exercises, providing additional liquidity. Despite the continued loss per share, the better-than-expected performance may offer some relief to investors amid ongoing financial challenges typical for biopharmaceutical firms in development stages.
Topics: Earnings Financials